Drugs.com - New Drug Approvals

Spravato (esketamine) Approved in the U.S. as the First and Only Monotherapy for Adults with Treatment-Resistant Depression

Titusville, New Jersey, January 21, 2025 – Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for Spravato (esketamine) CIII nasal spray, making...

Feb 9, 2025 - 22:25
 0
Spravato (esketamine) Approved in the U.S. as the First and Only Monotherapy for Adults with Treatment-Resistant Depression
Titusville, New Jersey, January 21, 2025 – Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for Spravato (esketamine) CIII nasal spray, making...
Read More

Tags:

Previous Article

FDA Approves Grafapex (treosulfan) Preparative Regimen for Allogeneic Hematopoie...

Next Article

FDA Approves Datroway (datopotamab deruxtecan-dlnk) for Patients with Previously...

Related Posts

FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Treatment of Diabetic Macular Edema

FDA Approves Genentech’s Susvimo as the First and Only ...

Feb 9, 2025  0

Tevimbra Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy

Tevimbra Approved in U.S. for First-line Treatment of G...

Feb 9, 2025  0

Calquence Plus Chemoimmunotherapy Approved in the U.S. for Patients with Previously Untreated Mantle Cell Lymphoma

Calquence Plus Chemoimmunotherapy Approved in the U.S. ...

Feb 9, 2025  0